Anti-CYP3A4 Antibody, clone 2F2 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Cytochrome P450 3A4 (UniProt: P08684; also known as EC:1.14.14.1, 1,4-cineole 2-exo-monooxygenase, 1,8-cineole 2-exo-monooxygenase (EC:1.14.14.56), Albendazole monooxygenase (sulfoxide-forming) (EC:1.14.14.73), Albendazole sulfoxidase, CYPIIIA3, CYPIIIA4, Cholesterol 25-hydroxylase, Cytochrome P450 3A3, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450-PCN1, Nifedipine oxidase, Quinine 3-monooxygenase (EC:1.14.14.55)) is encoded by the CYP3A4 (also known as CYP3A3) gene (Gene ID: 1576) in human. CYP3A4, a member of the cytochrome P450 superfamily, is a heme-containing monooxygenase enzyme. It consists of a single polypeptide chain with an active site containing a heme prosthetic group that facilitates its enzymatic function. CYP3A4 plays a pivotal role in the metabolism of xenobiotics and endogenous compounds, including drugs, toxins, steroids, and lipids. It catalyzes oxidation reactions, such as hydroxylation and demethylation, which are critical for detoxification and excretion. As the most abundant P450 isoform in the liver and intestine, CYP3A4 is responsible for the metabolism of nearly half of all clinically used drugs, including anticoagulants, immunosuppressants, and chemotherapeutics. CYP3A4 is predominantly expressed in hepatocytes and enterocytes, with additional expression noted in the kidney, brain, and other tissues. Its subcellular localization is primarily within the endoplasmic reticulum, where it interacts with co-factors like NADPH-cytochrome P450 reductase to facilitate electron transfer during enzymatic reactions. The activity of CYP3A4 is highly variable among individuals due to genetic polymorphisms, environmental factors, and regulatory influences such as inflammatory mediators and hormones. This variability can significantly affect drug efficacy and toxicity, contributing to interindividual differences in pharmacokinetics. CYP3A4 is regulated by nuclear receptors including pregnane X receptor (PXR) and vitamin D receptor (VDR), which respond to endogenous and exogenous ligands. These interactions mediate transcriptional activation of CYP3A4 under conditions of high xenobiotic exposure. The enzyme also has clinically significant interactions with other proteins, such as multidrug resistance protein 1 (MDR1), which impacts drug transport and metabolism. Furthermore, CYP3A4 is implicated in drug-drug interactions, particularly when inhibitors or inducers of the enzyme alter the metabolism of co-administered drugs, potentially leading to adverse effects like toxicity or therapeutic failure. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

KLH-conjugated linear peptide corresponding to 21 amino acids from the N-terminal half of human CYP3A4.

Quality Control Testing

Evaluated by Western Blotting with human liver microsomal preparation.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected CYP3A4 in human liver microsomal preparation.

Tested Applications

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CYP3A4 in human liver tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound with CYP3A4 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens and experimental conditions may vary with the end user.

Clone 2F2 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects CYP3A4. It targets an epitope within 21 amino acids from the N-terminal half.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.